TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Controlled Trial of Sunlight and Calcium Supplementation to Reduce Vitamin D Deficiency and Falls in Older People in Residential Care
Brief Summary: The proposed study will determine the effect of a public health strategy (ie. increased sun light exposure and increased calcium intake) to reduce falls in older people in residential care using a randomised trial. The primary hypothesis of the trial is that increased appropriate sun light exposure will reduce falls, improve 25 hydroxy vitamin D (25OHD) levels and lower parathyroid hormone (PTH) levels. Secondary hypotheses are that the intervention will reduce accelerated bone turnover, reduce fractures, improve motor function and improve mood.


Options:
A: Arm Label: Group A, Sunlight; Type: ACTIVE_COMPARATOR; Interventions: Other: Sunlight | Arm Label: Group B, sunlight and calcium; Type: ACTIVE_COMPARATOR; Interventions: Other: Sunlight and calcium | Arm Label: Group C; Type: NO_INTERVENTION; Interventions: Other: control | Intervention Type: OTHER; Name: Sunlight; Assigned to Arm(s): Group A, Sunlight | Intervention Type: OTHER; Name: Sunlight and calcium; Assigned to Arm(s): Group B, sunlight and calcium | Intervention Type: OTHER; Name: control; Assigned to Arm(s): Group C
B: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): N/A
C: Arm Label: Whole Body Vibration Group; Type: EXPERIMENTAL; Interventions: Device: Vibrosphère device | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Vibrosphère device; Assigned to Arm(s): Whole Body Vibration Group
D: Arm Label: Person-centered Care; Type: EXPERIMENTAL; Interventions: Other: Person-centered Care, Other: Optimised Treatment | Arm Label: Optimised Treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Optimised Treatment | Intervention Type: OTHER; Name: Person-centered Care; Assigned to Arm(s): Person-centered Care | Intervention Type: OTHER; Name: Optimised Treatment; Assigned to Arm(s): Optimised Treatment, Person-centered Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Functional Strength Training on Weakness and Function of the Lower Limb After Stroke
Brief Summary: The purpose of this study is to test the hypothesis that adding functional strength training to UK conventional therapy improves muscle function and walking than either UK conventional therapy alone or increased intensity of UK conventional therapy


Options:
A: Intervention Type: BEHAVIORAL; Name: Conventional UK Physical therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Increased intensity of UK conventional physical therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: UK conventional physical therapy plus functional strength training; Assigned to Arm(s): N/A
B: Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Sham | Arm Label: Conventional Paired tDCS; Type: ACTIVE_COMPARATOR; Interventions: Device: Conventional Paired tDCS | Arm Label: Conventional Unpaired tDCS; Type: ACTIVE_COMPARATOR; Interventions: Device: Conventional Unpaired tDCS | Arm Label: Late LTP-like Plasticity tDCS; Type: EXPERIMENTAL; Interventions: Device: Late LTP-like Plasticity tDCS | Intervention Type: DEVICE; Name: Sham; Assigned to Arm(s): Sham | Intervention Type: DEVICE; Name: Conventional Paired tDCS; Assigned to Arm(s): Conventional Paired tDCS | Intervention Type: DEVICE; Name: Conventional Unpaired tDCS; Assigned to Arm(s): Conventional Unpaired tDCS | Intervention Type: DEVICE; Name: Late LTP-like Plasticity tDCS; Assigned to Arm(s): Late LTP-like Plasticity tDCS
C: Arm Label: real tDCS; Type: ACTIVE_COMPARATOR; Interventions: Device: tDCS | Arm Label: Sham tDCS; Type: PLACEBO_COMPARATOR; Interventions: Device: tDCS | Intervention Type: DEVICE; Name: tDCS; Assigned to Arm(s): Sham tDCS, real tDCS
D: Arm Label: Real stimulation; Type: ACTIVE_COMPARATOR; Interventions: Device: tdcs (ELDITH, Neuroconn, Ilmenau, Germany) | Arm Label: Sham stimulation; Type: SHAM_COMPARATOR; Interventions: Device: tdcs (ELDITH, Neuroconn, Ilmenau, Germany) | Intervention Type: DEVICE; Name: tdcs (ELDITH, Neuroconn, Ilmenau, Germany); Assigned to Arm(s): Real stimulation, Sham stimulation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Functional Strength Training on Weakness and Function of the Lower Limb After Stroke
Brief Summary: The purpose of this study is to test the hypothesis that adding functional strength training to UK conventional therapy improves muscle function and walking than either UK conventional therapy alone or increased intensity of UK conventional therapy


Options:
A: Intervention Type: BEHAVIORAL; Name: Conventional UK Physical therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Increased intensity of UK conventional physical therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: UK conventional physical therapy plus functional strength training; Assigned to Arm(s): N/A
B: Arm Label: STARFISH intervention; Type: EXPERIMENTAL; Interventions: Behavioral: STARFISH intervention | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: STARFISH intervention; Assigned to Arm(s): STARFISH intervention
C: Arm Label: Intensive Walking; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive Walking | Arm Label: Conventional Physical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Conventional Physical Therapy | Intervention Type: BEHAVIORAL; Name: Intensive Walking; Assigned to Arm(s): Intensive Walking | Intervention Type: BEHAVIORAL; Name: Conventional Physical Therapy; Assigned to Arm(s): Conventional Physical Therapy
D: Arm Label: With isokinetic strength training; Type: EXPERIMENTAL; Interventions: Other: isokinetic strength training | Arm Label: without isokinetic strength training; Type: PLACEBO_COMPARATOR; Interventions: Other: passive motion | Intervention Type: OTHER; Name: isokinetic strength training; Assigned to Arm(s): With isokinetic strength training | Intervention Type: OTHER; Name: passive motion; Assigned to Arm(s): without isokinetic strength training

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Bio-behavioral Lung Cancer Prevention Program
Brief Summary: The overall goal of this research is to increase our understanding of the role of individual genetic differences in response to bupropion treatment and the psychobiological mechanisms by which genetic and treatment factors interact in the smoking cessation process. The ultimate objective is to provide information necessary to match bupropion vs. behavioral counseling cessation treatment to those smokers with the greatest need and likelihood of benefit. This study is a double-blind randomized placebo-controlled clinical trial of bupropion HCL (brand name Zyban) in adult male and female smokers. The factorial design includes one treatment factor (bupropion 300 mg/day + counseling vs. placebo + counseling) and several subject factors (e.g. genotype, personality). Smoking history, psychological status will be assessed at baseline and blood will be drawn for genotyping. Bupropion or placebo will be delivered over a 10-week treatment period and subjects will be instructed to quit smoking after two weeks of medication (week 3 of treatment). All subjects will also receive a 7-week group behavioral smoking cessation treatment (over an 11 week period). This study may yield information that will help clinicians identify the most effective smoking cessation treatment for a particular patient, based on his/her background.


Options:
A: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: support and visits, Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: support and visits, Drug: placebo | Intervention Type: BEHAVIORAL; Name: support and visits; Assigned to Arm(s): placebo, varenicline | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Intervention Type: DRUG; Name: zyban; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: SSR591813L (dianicline); Assigned to Arm(s): N/A
D: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pil; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Sugar Pil

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Administration of L-carnitine in Hemodialysis Patients: Double Blind Randomized Trial Versus Placebo
Brief Summary: Hemodialysis is a cause of carnitine deficiency. The deficiency of carnitine induces an anemia by an increase fragility of the red blood cells, a muscular fatigue and a cardiac dysfunction. We proposed to evaluate the benefit of an early administration of L-carnitine in hemodialysis patients. The patients should be included in the first month after the start of chronic hemodialysis, randomized to receive L-carnitine or placebo and should be followed-up during one year.


Options:
A: Arm Label: UCR; Type: ACTIVE_COMPARATOR; Interventions: Device: UCR | Arm Label: UTR; Type: ACTIVE_COMPARATOR; Interventions: Device: UTR | Arm Label: conventional dialysis; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: UCR; Assigned to Arm(s): UCR | Intervention Type: DEVICE; Name: UTR; Assigned to Arm(s): UTR
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: L-Carnitine | Intervention Type: DRUG; Name: L-Carnitine; Assigned to Arm(s): 1
C: Arm Label: placebo; Type: OTHER; Interventions: Drug: placebo | Arm Label: L-carnitine; Type: OTHER; Interventions: Drug: L-carnitine | Intervention Type: DRUG; Name: L-carnitine; Assigned to Arm(s): L-carnitine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Glucose solution; Type: ACTIVE_COMPARATOR; Interventions: Drug: PD solution containing glucose | Arm Label: Glucose and L-carnitine solution; Type: EXPERIMENTAL; Interventions: Drug: PD solution containing glucose and L-carnitine | Intervention Type: DRUG; Name: PD solution containing glucose; Assigned to Arm(s): Glucose solution | Intervention Type: DRUG; Name: PD solution containing glucose and L-carnitine; Assigned to Arm(s): Glucose and L-carnitine solution

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Epoetin Omega in Patients Undergoing Regular Dialysis. Part II: Comparative Trial Versus Epoetin Alfa
Brief Summary: The two epoetins, Epoetin alfa, a well established drug to treat renal anemia and Epoetin Omega, that differs from Epoetin alfa in the sugar moiety of the molecule were compared in regard of efficacy and safety to treat end stage renal disease anemia. Study hypothesis was that Epoetin Omega is non-inferior to Epoetin alfa in correcting renal anemia in dialysis patients. A 12-weeks randomized comparative efficacy study was performed including 77 end stage renal disease patients (epoetin omega:n=39, epoetin alfa: n=38). In the intent-to-treat analysis, average weekly difference in hemoglobin versus baseline value was higher in omega-treated patients: 1.94+-0.81 vs. 1.23+-0.62 g/dl. The unadjusted and adjusted omega-alfa differences were 0.71 g/dl (95%CI 0.38 to 1.04; p\<0.001) and 0.78 g/dl (0.49 to 1.08;p\<0.001), respectively. Average weekly epoetin dose was lower in the omega group: 87+-25 vs. 108+-21 IU/kg. The unadjusted and adjusted omega-alfa differences were -21IU/kg (-32 to -11; p\<0.001) and -24IU/kg (-35 to -13; p\<0.001), respectively. Epoetins were comparably well tolerated. In dialysis patients, subcutaneous epoetin omega apparently provides a greater anti-anemic effect per administered dose (IU) than epoetin alfa.


Options:
A: Intervention Type: DRUG; Name: Epoetin; Assigned to Arm(s): N/A
B: Arm Label: Early Epoetin Beta Therapy; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta [NeoRecormon] | Arm Label: Late Epoetin Beta Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin beta [NeoRecormon] | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Early Epoetin Beta Therapy | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Late Epoetin Beta Therapy
C: Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: GerEPO; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Epoetin Omega in Patients Undergoing Regular Dialysis. Part II: Comparative Trial Versus Epoetin Alfa
Brief Summary: The two epoetins, Epoetin alfa, a well established drug to treat renal anemia and Epoetin Omega, that differs from Epoetin alfa in the sugar moiety of the molecule were compared in regard of efficacy and safety to treat end stage renal disease anemia. Study hypothesis was that Epoetin Omega is non-inferior to Epoetin alfa in correcting renal anemia in dialysis patients. A 12-weeks randomized comparative efficacy study was performed including 77 end stage renal disease patients (epoetin omega:n=39, epoetin alfa: n=38). In the intent-to-treat analysis, average weekly difference in hemoglobin versus baseline value was higher in omega-treated patients: 1.94+-0.81 vs. 1.23+-0.62 g/dl. The unadjusted and adjusted omega-alfa differences were 0.71 g/dl (95%CI 0.38 to 1.04; p\<0.001) and 0.78 g/dl (0.49 to 1.08;p\<0.001), respectively. Average weekly epoetin dose was lower in the omega group: 87+-25 vs. 108+-21 IU/kg. The unadjusted and adjusted omega-alfa differences were -21IU/kg (-32 to -11; p\<0.001) and -24IU/kg (-35 to -13; p\<0.001), respectively. Epoetins were comparably well tolerated. In dialysis patients, subcutaneous epoetin omega apparently provides a greater anti-anemic effect per administered dose (IU) than epoetin alfa.


Options:
A: Arm Label: RO0503821 (1x/2 Weeks); Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: Darbepoetin (1x/1-2 Weeks); Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin (1x/1-2 Weeks) | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): RO0503821 (1x/2 Weeks)
B: Intervention Type: DRUG; Name: Epoetin; Assigned to Arm(s): N/A
C: Arm Label: Epoetin Bio-Manguinhos; Type: EXPERIMENTAL; Interventions: Drug: Epoetin Alfa-BioManguinhos | Arm Label: EPO-BioSimilar; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin Alfa-BioSimilar | Intervention Type: DRUG; Name: Epoetin Alfa-BioManguinhos; Assigned to Arm(s): Epoetin Bio-Manguinhos | Intervention Type: DRUG; Name: Epoetin Alfa-BioSimilar; Assigned to Arm(s): EPO-BioSimilar
D: Arm Label: High Hb group; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Low Hb group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): High Hb group, Low Hb group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open Label, Randomised, Parallel Group, Multicentre, Ph III Study To Assess Efficacy, Safety & Tolerability Of Gefitinib (IRESSA™) Versus Carboplatin/Paclitaxel DC As 1st-Line Treatment In Selected Patients With Stage IIIB / IV NSCLC In Asia
Brief Summary: The purpose of this study is to compare gefitinib with carboplatin / paclitaxel doublet chemotherapy given as first line treatment in terms of progression free survival in selected NSCLC patients with the objective of demonstrating non-inferiority.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Gefitinib | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): 2
B: Arm Label: 250 mg Gefitinib/500 mg Pemetrexed; Type: EXPERIMENTAL; Interventions: Drug: Gefitinib, Drug: Pemetrexed | Arm Label: 250 mg Gefitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gefitinib | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): 250 mg Gefitinib, 250 mg Gefitinib/500 mg Pemetrexed | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): 250 mg Gefitinib/500 mg Pemetrexed
C: Arm Label: Alimta; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pemetrexed (Alimta) | Arm Label: IRESSA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gefitinib (IRESSA) | Intervention Type: DRUG; Name: Pemetrexed (Alimta); Assigned to Arm(s): Alimta | Intervention Type: DRUG; Name: Gefitinib (IRESSA); Assigned to Arm(s): IRESSA
D: Arm Label: Pemetrexed/Cisplatin/Gefitinib; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed, Drug: Cisplatin, Drug: Gefitinib | Arm Label: Pemetrexed/Cisplatin; Type: EXPERIMENTAL; Interventions: Drug: Pemetrexed, Drug: Cisplatin | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Pemetrexed/Cisplatin, Pemetrexed/Cisplatin/Gefitinib | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Pemetrexed/Cisplatin, Pemetrexed/Cisplatin/Gefitinib | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): Pemetrexed/Cisplatin/Gefitinib

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open Label, Randomised, Parallel Group, Multicentre, Ph III Study To Assess Efficacy, Safety & Tolerability Of Gefitinib (IRESSA™) Versus Carboplatin/Paclitaxel DC As 1st-Line Treatment In Selected Patients With Stage IIIB / IV NSCLC In Asia
Brief Summary: The purpose of this study is to compare gefitinib with carboplatin / paclitaxel doublet chemotherapy given as first line treatment in terms of progression free survival in selected NSCLC patients with the objective of demonstrating non-inferiority.


Options:
A: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-FU, Drug: folinic acid, Drug: irinotecan, Drug: cetuximab | Arm Label: Arm B; Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-FU, Drug: folinic acid, Drug: irinotecan, Drug: bevacizumab | Intervention Type: DRUG; Name: 5-FU; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: folinic acid; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: irinotecan; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: cetuximab; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): Arm B
B: Arm Label: Cetuximab Plus FOLFIRI; Type: EXPERIMENTAL; Interventions: Drug: Cetuximab, Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan) | Arm Label: FOLFIRI Alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan) | Intervention Type: DRUG; Name: Cetuximab; Assigned to Arm(s): Cetuximab Plus FOLFIRI | Intervention Type: DRUG; Name: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan); Assigned to Arm(s): Cetuximab Plus FOLFIRI, FOLFIRI Alone
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Gefitinib | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): 2
D: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Cetuximab, Drug: chemotherapy of mFOLFOX6 or FOLFIRI | Arm Label: Arm B; Type: ACTIVE_COMPARATOR; Interventions: Drug: chemotherapy of mFOLFOX6 or FOLFIRI | Intervention Type: DRUG; Name: Cetuximab; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: chemotherapy of mFOLFOX6 or FOLFIRI; Assigned to Arm(s): Arm A, Arm B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open Label, Randomised, Parallel Group, Multicentre, Ph III Study To Assess Efficacy, Safety & Tolerability Of Gefitinib (IRESSA™) Versus Carboplatin/Paclitaxel DC As 1st-Line Treatment In Selected Patients With Stage IIIB / IV NSCLC In Asia
Brief Summary: The purpose of this study is to compare gefitinib with carboplatin / paclitaxel doublet chemotherapy given as first line treatment in terms of progression free survival in selected NSCLC patients with the objective of demonstrating non-inferiority.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Erlotinib | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Gemcitabin, Drug: Docetaxel, Drug: Cisplatin | Intervention Type: DRUG; Name: Erlotinib; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Gemcitabin; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): B
B: Arm Label: erlotinib; Type: EXPERIMENTAL; Interventions: Drug: erlotinib | Arm Label: gemcitabine/carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: gemcitabine/carboplatin | Intervention Type: DRUG; Name: erlotinib; Assigned to Arm(s): erlotinib | Intervention Type: DRUG; Name: gemcitabine/carboplatin; Assigned to Arm(s): gemcitabine/carboplatin
C: Arm Label: Icotinib; Type: EXPERIMENTAL; Interventions: Drug: Icotinib | Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Chemotherapy | Intervention Type: DRUG; Name: Icotinib; Assigned to Arm(s): Icotinib | Intervention Type: DRUG; Name: Chemotherapy; Assigned to Arm(s): Chemotherapy
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Gefitinib | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel | Intervention Type: DRUG; Name: Gefitinib; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): 2

Answer: D